Literature DB >> 21170595

Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population.

Pedro Weslley Rosario1.   

Abstract

The objective of this study was to evaluate the frequency of acromegaly in adults with diabetes mellitus (DM) or glucose intolerance (GI) and to estimate its prevalence in the general population. A total of 2,270 patients with DM or GI and age from 20 to 70 years were studied. Patients with known pituitary disease and pregnant women were excluded. Serum IGF-1 was measured in all subjects and, if elevated, a new measurement was obtained together with the measurement of GH in the oral glucose tolerance test (OGTT). Patients with persistently elevated IGF-1 and inadequate suppression of GH were submitted to magnetic resonance imaging (MRI). Acromegaly was not suspected by the assistant physician in any of the patients. Six patients had persistently elevated IGF-1 and inadequate suppression of GH in the OGTT (without other conditions associated with GH or IGF-1 elevation). Pituitary adenoma was detected by MRI in three patients, and two subjects presented an acromegalic phenotype. Two patients were submitted to transsphenoidal surgery, with immunohistochemistry confirming immunoreactivity for GH. Another patient was treated with octreotide LAR which resulted in the normalization of IGF-1 and GH. Considering a prevalence of DM or GI of 20% in adults and the occurrence of these co-morbidities in 55% of patients with acromegaly, the frequency of 3/2,270 found in this study permits to estimate 480 cases/1,000,000 adults. The present results suggest that the prevalence of acromegaly is underestimated and further studies are needed to evaluate the cost-effectiveness of biochemical screening in certain groups of patients.

Entities:  

Mesh:

Year:  2011        PMID: 21170595     DOI: 10.1007/s11102-010-0281-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  32 in total

1.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

2.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.

Authors:  A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  Acromegaly without imaging evidence of pituitary adenoma.

Authors:  Russell R Lonser; Bogdan A Kindzelski; Gautam U Mehta; John A Jane; Edward H Oldfield
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

4.  Normal values of serum IGF-1 in adults: results from a Brazilian population.

Authors:  Pedro Weslley Rosario
Journal:  Arq Bras Endocrinol Metabol       Date:  2010

5.  Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration?

Authors:  Sameera Daud; Amir H Hamrahian; Robert J Weil; Marwan Hamaty; Richard A Prayson; Leann Olansky
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

6.  Growth hormone after oral glucose overload: revision of reference values in normal subjects.

Authors:  Pedro W S Rosário; Mariana S Furtado
Journal:  Arq Bras Endocrinol Metabol       Date:  2008-10

7.  Acromegaly. Clinical and biochemical features in 500 patients.

Authors:  S Ezzat; M J Forster; P Berchtold; D A Redelmeier; V Boerlin; A G Harris
Journal:  Medicine (Baltimore)       Date:  1994-09       Impact factor: 1.889

8.  Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed.

Authors:  Tirissa J Reid; Kalmon D Post; Jeffrey N Bruce; M Nabi Kanibir; Carlos M Reyes-Vidal; Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-16       Impact factor: 3.478

9.  The influence of age on the GH-IGF1 axis in patients with acromegaly.

Authors:  Keiji Tanimoto; Naomi Hizuka; Izumi Fukuda; Kazue Takano; Toshiaki Hanafusa
Journal:  Eur J Endocrinol       Date:  2008-07-24       Impact factor: 6.664

10.  Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30-69 years in Ribeirão Preto (São Paulo), Brazil.

Authors:  Maria Teresa Torquato; Renan Magalhães Montenegro Júnior; Luis Atílio Viana; Rui Augusto de Souza; Carla Márcia Lanna; Júlio César Lucas; Cláudio Bidurin; Milton Cesar Foss
Journal:  Sao Paulo Med J       Date:  2003-11-06       Impact factor: 1.044

View more
  17 in total

Review 1.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

2.  Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus.

Authors:  Hiromitsu Iwata; Kengo Sato; Ryutaro Nomura; Yusuke Tabei; Ichiro Suzuki; Naoki Yokota; Mitsuhiro Inoue; Seiji Ohta; Shozo Yamada; Yuta Shibamoto
Journal:  J Neurooncol       Date:  2016-03-09       Impact factor: 4.130

Review 3.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units.

Authors:  Pedro Weslley Rosario; Maria Regina Calsolari
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

6.  Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.

Authors:  Shaun J Kilty; Myriam G M Hunink; Lisa Caulley; Eline Krijkamp; Mary-Anne Doyle; Kednapa Thavorn; Fahad Alkherayf; Nick Sahlollbey; Selina X Dong; Jason Quinn; Stephanie Johnson-Obaseki; David Schramm
Journal:  Pituitary       Date:  2022-08-27       Impact factor: 3.599

7.  Safety and specificity of the growth hormone suppression test in patients with diabetes.

Authors:  Pedro Weslley Rosario; Maria Regina Calsolari
Journal:  Endocrine       Date:  2014-05-17       Impact factor: 3.633

8.  Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter.

Authors:  Stijn J M Niessen; Yaiza Forcada; Panagiotis Mantis; Christopher R Lamb; Norelene Harrington; Rob Fowkes; Márta Korbonits; Ken Smith; David B Church
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

Review 9.  Need for improved monitoring in patients with acromegaly.

Authors:  Julie M Silverstein
Journal:  Endocr Connect       Date:  2015-09-17       Impact factor: 3.335

10.  Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.

Authors:  Roberto Salvatori; Whitney W Woodmansee; Mark Molitch; Murray B Gordon; Kathleen G Lomax
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.